Recombinant Protein Market to Partake Significant Development During 2018-2026

Recombinant Protein Market to Partake Significant
Development During 2018-2026
Recombinant Protein Market, by Product Type (Hormones, Growth Factors,
Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune
Checkpoint Regulators, and Others), By Application (Drug Discovery &
Development, Biopharmaceutical Production, Basic Research, and Others), By
End User (Biopharmaceutical Companies, Academic & Research Institutes,
Contract Research Organizations, and Others), and Region - Global Industry
insights, and Forecast till 2025
Recombinant proteins have immense potential in cancer therapy research and development. For
instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical
stage) are utilized from recombinant proteins category for cancer therapy research. Increased
understanding of oncogenic signaling pathways and proteins involved in the same has increased the
targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and
antibodies are used. These proteins are used extensively by researchers to research cancer signaling
pathways and functioning. The Global Recombinant Protein Market was valued at US$ 347.2
million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017–
2025).
Recombinant immune checkpoint such as PD-1/PD-L1 Inhibitor 1 and PD-1/PD-L1 Inhibitor 2, which
directly targets programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) are used
for research purposes. Moreover, proteins such as CD226, CD40 Ligand/TRAP, and Human CellExp
CTLA4/CD152 are extensively used in cancer therapies research.
Market Dynamics
Increasing demand for recombinant proteins for basic research has supported growth of recombinant
protein market. Manufacturers are involved in recombinant protein product innovation in order to
improve research outcomes along with improvements in other areas such as expression techniques, and
protein purification techniques, which compliments growth of the recombinant protein market. The
market is expected to gain significant growth, owing increasing adoption of biologics and biosimilars,
which will in turn impact recombinant proteins market, along with rising prevalence of chronic
diseases such as cancer. Furthermore, availability of wide number of innovative recombinant proteins
from various sources such as human and animal, lack of suitable alternative for basic protein related
therapies research, and increasing demand for biological products is expected to fuel growth of the
market.
Get The PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1516
Technological advancement in production of recombinant protein is expected to fuel growth of
the recombinant protein market
Advancement in technologies in various areas associated with or facilitating recombinant protein
production have supported growth of recombinant protein market. For instance, development of
alternative expression technologies such as mammalian cell expression, baculovirus expression, and
E.coli expression, development of alternative cell lines, and enhanced cell culture systems have
simplified and optimized recombinant protein processes. Furthermore, advanced chromatography
protein purification methods such as FPLC and HPLC help in providing highly purified clinical grade
recombinant proteins. Clustered regularly interspaced short palindromic repeats (CRISPR) technique is
a genome editing technique used to target destruction in human cells and can improve recombinant
protein production.
Moreover, advancements in bioreactor systems have improved the product’s output within shorter time.
According to National Centre for Biotechnology Information (NCBI), in 2014, about 65.6% of clinical
scale manufacturers and 42% of commercial manufacturers adopted single use bioreactor for
improvement in their bioprocessing.
Some major players operating in the recombinant protein market include Crown Bioscience, Inc.,
ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein
Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript
Biotech Corporation.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1516
Increasing research & development expenditure on biologic drugs is expected to boost demand
for recombinant proteins for research purposes
Biopharmaceutical organizations are focusing on research and development of novel biosimilars for life
threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and
certain rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers
of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and
development in 2015, of which, majority was by all biopharmaceutical companies in the U.S. Rare
disease medical space holds potential as there is relatively low competition. This is owing to less
understanding of the disease progression pathways and entities. Therefore, companies could focus on
R&D for development of biologics and subsequently biosimilars in this space.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research.

Download Report